Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$983.80 USD
-10.15 (-1.02%)
Updated May 22, 2024 03:59 PM ET
After-Market: $984.18 +0.38 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Regeneron Pharmaceuticals, Inc. [REGN]
Reports for Purchase
Showing records 361 - 380 ( 591 total )
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
CAPELLA Hits Bump; Eylea Alone Remains Strong Therapy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
First Breakthrough, Now Priority Review for Dupilumab
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Fasinumab Monetized; It''s Been a Long Road for the Class; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q16 Results; Blocking and Tackling on Revenue Growth and Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dupilumab Continues to Shine Ahead of 3Q16 BLA Filing
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q16 Results; The Juggernaut Pushes Forward; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Regeneron reported Q1 results
Provider: G.RESEARCH, LLC